Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation

B-cell depleting anti-CD20 monoclonal antibody therapies are being increasingly used as long-term maintenance therapy for neuroinflammatory disease compared to many non-neurological diseases where they are used as remission-inducing agents. While hypogammaglobulinaemia is known to occur in over half...

Descripción completa

Detalles Bibliográficos
Autores principales: Tallantyre, E. C., Whittam, D. H., Jolles, S., Paling, D., Constantinesecu, C., Robertson, N. P., Jacob, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2018
Materias:
Original Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5937879/
https://www.ncbi.nlm.nih.gov/pubmed/29511864
http://dx.doi.org/10.1007/s00415-018-8812-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5937879/
https://www.ncbi.nlm.nih.gov/pubmed/29511864
http://dx.doi.org/10.1007/s00415-018-8812-0

Ejemplares similares